Welcome to the MedLibrary.org Wikipedia Supplement on Directive 65/65/EEC1 -- Please Click to Return to Front Page

Directive 65/65/EEC1 was the first European pharmaceutical directive. The directive was a reaction to the Thalidomide tragedy in the early 1960s, when thousands of babies were born with deformities as a result of their mothers taking thalidomide during pregnancy. The directive aimed to establish and maintain a high level of protection for public health in Europe.^{citation needed} The idea behind the directive was that no medicinal product should ever again be marketed in the European Union without prior authorisation.^{citation needed}

See also

• EudraLex
• Kefauver Harris Amendment
• Regulation of therapeutic goods
• European Medicines Agency

References

• Maio G., On the history of the Contergan (thalidomide) catastrophe in the light of drug legislation, Dtsch Med Wochenschr. 2001 Oct 19;126(42):1183-6.
• Shah RR., Thalidomide, drug safety and early drug regulation in the UK, Adverse Drug React Toxicol Rev. 2001 Dec;20(4):199-255.

External links

• Directive 65/65/EEC1
• New medicines legislation (overview)

This health-related article is a stub. You can help Wikipedia by expanding it.

Wikipedia content modification information:

• This page was last modified on 21 April 2007, at 10:21.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Directive 65/65/EEC1".

The URL for this specific entry is:

• http://medlibrary.org/medwiki/Directive_65/65/EEC1

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.